Administrative Core

行政核心

• 批准号: 7982960
• 负责人: JOSEPH M. DESIMONE
• 金额: $ 16.81万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-01 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7982960
• 关键词: Adherence; Area; Arts; Basic Science; Breast; Budgets; CCNE1 gene; Caliber; Cancer Patient; Clinic; Clinical; Clinical Sciences; Clinical and Translational Science Awards; Communication; Communities; Consultations; Dependency; Development; Disease Management; Doctor of Medicine; Doctor of Philosophy; Drug Delivery Systems; Education and Outreach; Effectiveness; Electronic Mail; Ensure; Environment; Funding; General Population; Goals; Institutes; Institution; Laboratories; Leadership; Malignant Neoplasms; Medical; Nanotechnology; North Carolina; Patient Care; Pharmacy Schools; Pharmacy facility; Play; Principal Investigator; Public Health; Recording of previous events; Research; Research Infrastructure; Research Personnel; Research Project Grants; Resources; Role; Schedule; Schools; Science; Scientist; Solutions; Specialized Program of Research Excellence; Technology; TimeLine; Translational Research; UNC Lineberger Comprehensive Cancer Center; Universities; Update; Work; anticancer research; drug development; experience; fight against; innovation; interest; medical schools; meetings; member; multidisciplinary; nanofabrication; nanomaterials; nanomedicine; nanoparticle; nanoscience; oncology; physical science; programs; success; web site; working group

Section N2. Research Team and Research Capabilities, Center Organization and Infrastructure (Administrative Core) 1) Research Team Outline the major strength of the team and specific senior investigators In the context of the proposed area of focus; Successful application of nanotechnology to cancer requires an interactive and diverse team with innovative and creative solutions. The innovation and goals proposed In our CCNE are challenging but mirror the strength of our researchers and partnerships, especially since our focus is to transition these nanotechnologies to cancer disease management. Our team reflects that focus and combines expertise in the basic science of nanotechnology working In concert with translational research oriented clinicians who can help both the broad and the specific research agenda to maximize a direct impact on patient care. In addition, we have successfully combined researchers from four schools on the UNC campus: the Schools of Medicine, Arts and Sciences, Pharmacy and Public Health. This diversity of expertise and interests will help to ensure the success of our program. Our research team is led by Co-Principal Investigators, Joseph M. DeSimone, Ph.D. and Joel Tepper, M.D., who bring extensive experience in scientific leadership across the continuum from basic science to clinical development. We have emphasized this bridging of basic and clinical sciences throughout our proposal to demonstrate our understanding of and commitment to the challenge of bringing nanotechnology applications to cancer patients. Our projects feature nanotechnologies that are singular to the University of North Carolina at Chapel Hill, build on innovative ideas that have originated within our group, and reflect the highest caliber of scientists who discovered and developed them. We are confident that our mix of ideas, people and technologies is ideally suited to deliver on the promise of Nanomedicine. The University of North Carolina at Chapel Hill prides itself on being a leading institute in both medical and physical sciences and also providing and facilitating an environment of inter-disciplinary interactions. The cancer research community at UNC is anchored by the UNC Lineberger Comprehensive Cancer Center with a 35-year history. It is further strengthened by the presence of two NCI Specialized Programs of Research Excellence (SPOREs) in Breast and Gl cancer. The physical sciences aspects of our center are supported by the newly formed Institute for Nanomedicine, the Institute for Advanced Materials, Nanoscience and Technology (lAM) and the Chapel Hill Analytical and Nanofabrication Laboratory (CHANL). The Center for Nanotechnology in Drug Delivery and the Translational Oncology and Nanoparticle Drug Development Initiative (TONDDI) Lab at the Eshelman School of Pharmacy help transition nanomaterial discoveries toward the clinic. The $50 million/year University Cancer Research Fund (UCRF) and UNC's Clinical and Translational Science Award (CTSA) further enhance the entrepreneurial and translational aspects of our efforts of bringing relief to cancer patients. Our Center leadership will have all these resources to support a cohesive, stimulating, and effective CCNE. Our team and resources are discussed in more detail in the following sections.

N2 节。研究团队和研究能力、中心组织和基础设施 （行政核心） 1) 研究团队 概述该团队的主要实力和特定的高级研究人员在拟议的重点领域的背景下； 纳米技术在癌症上的成功应用需要一个互动且多元化的团队提供创新和创造性的解决方案。我们的 CCNE 中提出的创新和目标具有挑战性，但反映了我们研究人员和合作伙伴的实力，特别是因为我们的重点是将这些纳米技术转变为癌症疾病管理。我们的团队反映了这一重点，并将纳米技术基础科学的专业知识与转化研究导向的临床医生相结合，他们可以帮助广泛的 以及具体的研究议程，以最大限度地提高对患者护理的直接影响。此外，我们还成功地将来自北卡罗来纳大学校园内四所学校的研究人员结合起来：医学院、艺术与科学学院、药学院和公共卫生学院。这种专业知识和兴趣的多样性将有助于确保我们计划的成功。 我们的研究团队由联合首席研究员 Joseph M. DeSimone 博士领导。乔尔·泰珀（Joel Tepper）医学博士在从基础科学到临床开发的整个过程中带来了丰富的科学领导经验。我们在整个提案中都强调了基础科学和临床科学的桥梁，以表明我们对将纳米技术应用到人类中的挑战的理解和承诺。 癌症患者。我们的项目采用北卡罗来纳大学教堂山分校独有的纳米技术，建立在我们团队内部起源的创新理念之上，反映了发现和开发这些技术的科学家的最高水平。我们相信，我们的理念、人才和技术的结合非常适合实现纳米医学的承诺。 北卡罗来纳大学教堂山分校以其在医学和物理科学领域的领先地位而自豪，并提供和促进跨学科互动的环境。北卡罗来纳大学的癌症研究界以拥有 35 年历史的北卡罗来纳大学莱恩伯格综合癌症中心为基础。 NCI 在乳腺癌和胃肠道癌症方面的两个卓越研究专门计划 (SPORE) 的存在进一步加强了这一点。我们中心的物理科学方面得到了支持 新成立的纳米医学研究所、先进材料、纳米科学与技术研究所（LAM）和教堂山分析与纳米制造实验室（CHANL）。药物输送纳米技术中心以及埃谢尔曼药学院的转化肿瘤学和纳米颗粒药物开发计划 (TONDDI) 实验室帮助将纳米材料的发现转化为临床。每年 5000 万美元的大学癌症研究基金 (UCRF) 和北卡罗来纳大学的临床和转化科学奖 (CTSA) 进一步增强了我们为癌症患者提供救济的努力的创业和转化方面。我们中心的领导层将拥有所有这些资源来支持一个有凝聚力、激励性和有效的 CCNE。以下部分将更详细地讨论我们的团队和资源。